STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 150296

TO: Nyeemah Grazier **Location: REM-5B29&5C18** **Art Unit: 1626** **Wednesday, April 13, 2005** **Case Serial Number: 10/661947**	**From: Paul Schulwitz** **Location: Biotech-Chem Library** **REM-1A65** **Phone: 571-272-2527** **paul.schulwitz@uspto.gov**

Search Notes

Google →

– diebetes and glucagon

ACCESS DB # 150296

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Nyeemah Grazier Examiner #: 81802 Date: 4/8/05
Art Unit: 1626 Phone Number: 2-8781 Serial Number: 10/661,947
Location (Bldg/Room#): Rm5B29 (Mailbox #): _____ Results Format Preferred (circle): PAPER .DISK
****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Pyrazole Derivatives

Inventors (please provide full names): Charles Mowbray; David Price; Matthew Selby; Paul Stupple

Earliest Priority Date: 12/13/2002

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

*Claims 1-8, and 19

1) Structure Search



Formula (I)

AND



2) Process of Preparing Formula (I) using A, B, or C.



$L_1 = L_2 = H_2NNHCH_2CH_2OH$

****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 4/13
Searcher Prep & Review Time: 15
Online Time: 15

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
4 Structure (#)
_____ Bibliographic
_____ Litigation
_____ Fulltext
_____ Other

Vendors and cost where applicable

586.03 STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet
____ In-house sequence systems
____ Commercial ____ Oligomer ____ Score/Length
____ Interference ____ SPDI ____ Encode/Transl
_____ Other (specify)

10/661947
Claims 1-8, 19

CLAIMS

1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt, solvate or derivative thereof.

2. A pharmaceutical composition comprising the compound according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A compound according to claim 1 for use as a medicament.

4. A composition according to claim 2 for use as a medicament.

5. A compound according to claim 1 for use as a reverse transcriptase inhibitor or modulator.

6. A composition according to claim 2 for use as a reverse transcriptase inhibitor or modulator.

7. A compound according to claim 1 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

8. A composition according to claim 2 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

~~9. A method of treating~~ an HIV or a ~~genetically-related~~ retroviral infection, or a resulting acquired immune deficiency ~~syndrome~~ (AIDS), ~~comprising administering an effective amount~~ of a ~~compound according~~ to claim 1.

This Page Blank (uspto)

10. A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a composition according to claim 2.

11. A process for preparing the compound of formula (I)



(I)

or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

(A) condensing a compound of formulae (II), (VI) or (VII)



(II)



(VI)



(VII)

wherein L^1 and L^2 are leaving groups;

with the compound of formula (V)

$H_2NNHCH_2CH_2OH$ (V)

or a salt or hydrate thereof;

This Page Blank (uspto)

(B) alkylating the pyrazole of formula (XIII)



(XIII)

with an alkylating agent of formula (XIV)

$Lg\text{-}CH_2CH_2OH$ (XIV)

or a protected derivative thereof;

(C) deprotecting a protected derivative of the compound of formula (I);

and optionally converting the compound of formula (I) prepared by any one of steps (A) to (C) into a pharmaceutically acceptable salt, solvate or derivative thereof.

12. A process according to claim 11 wherein L^1 and L^2 are each independently selected from $-N(C_1\text{-}C_6\ alkyl)_2$ and $-N(CH_3)_2$.

13. A compound of formula (II)



(II)

14. A compound of formula (VI)

This Page Blank (uspto)



(VI)

wherein L^1 is a leaving group.

15. A compound of formula (VII)



(VII)

wherein L^2 is a leaving group.

16. A compund according to claim 14 or 15 wherein L^1 and L^2 are each independently selected from $-N(C_1-C_6\ alkyl)_2$ and $-N(CH_3)_2$.

17. A compound of formula (VIII)



(VIII)

18. A compound of formula (IX)



(IX).

19. A compound of formula (XIII)



(XIII)

This Page Blank (uspto)

=> d que
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L3 203 SEA FILE=REGISTRY SSS FUL L1
L4 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L9 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L11 2 SEA FILE=REGISTRY SSS FUL L9
L12 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L11(L)(RACT OR RCT OR RGT)/RL

L13 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L3(L)PREP/RL
L14 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13
L17 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 NOT L14

=> d l17 ibib abs hitstr 1-16

L17 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:308433 HCAPLUS
DOCUMENT NUMBER: 140:321352
TITLE: Preparation of pyrazole derivatives as HIV reverse transcriptase inhibitors
INVENTOR(S): Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Different Inv. entity b/c ≠ C. Mowbray

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031178	A1	20040415	WO 2003-IB4205	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004133002	A1	20040708	US 2003-669819	20030923
PRIORITY APPLN. INFO.:			GB 2002-23232 A	20021007
			US 2002-432859P P	20021211

Pub. Date 4/15/04

OTHER SOURCE(S): MARPAT 140:321352
GI



I



II

AB The title compds. [I; WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH or, when X = CH, may also be N; R1 = alkylene; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, Ph, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, and as such are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated, were prepared Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). Thus, reacting 3-(5-aminomethyl-3-methyl-1H-pyrazol-4-yloxy)-5-chlorobenzonitrile (preparation given) with Me 2-formylbenzoate in the presence of NaBH(OAc)3 and AcOH in CH2Cl2 afforded II which showed IC50 of 76 nM against HIV-1 reverse transcriptase. The pharmaceutical composition comprising the compound I is claimed.

IT **473923-70-5P 473923-73-8P 473924-23-1P 678992-37-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as HIV reverse transcriptase inhibitors)

RN 473923-70-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-73-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-23-1 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 678992-37-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-5-(bromomethyl)-4-(3,5-dicyanophenoxy)-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:292024 HCAPLUS
DOCUMENT NUMBER: 140:303665
TITLE: Preparation of pyrazole amides for treating HIV infections
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029051	A1	20040408	WO 2003-IB4071	20030915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005004129	A1	20050106	US 2003-669794	20030923
PRIORITY APPLN. INFO.:			GB 2002-22375 A	20020926
			GB 2002-23357 A	20021008
			US 2002-433220P P	20021213

OTHER SOURCE(S): MARPAT 140:303665
GI



I



II

AB The title compds. [I; WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH, or, when X = CH, may also be N; R1 = a bond, alkylene, R2 = H, alkyl, cycloalkyl,

etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were prepared and formulated. Thus, reacting [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic acid (preparation given) with 5,6,7,8-tetrahydro-[1,6]naphthyridine afforded II. The compds. I were tested for inhibition of HIV-1 reverse transcriptase enzyme (data were given for representative compds. I). The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

IT **473923-49-8P 473923-52-3P 473923-70-5P**
473923-73-8P 676994-56-2P 676994-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole amides for treating HIV infections)

RN 473923-49-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-52-3 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-70-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA

INDEX NAME)



RN 473923-73-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 676994-56-2 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 676994-57-3 HCAPLUS
CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:287840 HCAPLUS
DOCUMENT NUMBER: 140:303663
TITLE: Preparation of pyrazole derivatives as reverse transcriptase inhibitors
INVENTOR(S): Barba, Oscar; Jones, Lyn Howard
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029042	A1	20040408	WO 2003-IB4158	20030915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110816	A1	20040610	US 2003-669812	20030923
PRIORITY APPLN. INFO.:			GB 2002-22374 A	20020926
			GB 2002-23356 A	20021008
			US 2002-433402P P	20021213

OTHER SOURCE(S): MARPAT 140:303663
GI



I

AB The title compds. [I; R1 = (un)substituted 5-(6)membered heteroaryl containing (1) 1-4 N atoms or (2) 1-2 N atoms and 1 O atom or 1 S atom or (3) 1 or 2 O or S atoms; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were prepared and formulated. Thus, reacting 5-(3-ethyl-1-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yloxy)isophthalonitrile (preparation given) with 2-chloropyridine afforded I [R1 = 2-pyridyl; R2 = Me; R3 = Et; R4 = 3,5-dicyanophenyl] which showed IC50 of 5400 nM against HIV-1 reverse transcriptase. The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

IT **676995-20-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)

RN 676995-20-3 HCAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(2-pyridinyloxy)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **676995-24-7P 676995-26-9P 676995-27-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)

RN 676995-24-7 HCAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-4,5-dihydro-1-(2-hydroxyethyl)-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 676995-26-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 676995-27-0 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-5-(2-pyridinyloxy)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:174482 HCAPLUS

DOCUMENT NUMBER: 138:198678
TITLE: Small-molecule modulators of hepatocyte growth factor/scatter factor activities as drugs
INVENTOR(S): Pillarisetti, Sivaram; Goldberg, Itzhak D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003045559	A1	20030306	US 2001-896832	20010629
US 6589997	B2	20030708		
US 2003022924	A1	20030130	US 2001-26672	20011219
US 6610726	B2	20030826		
US 2003216459	A1	20031120	US 2003-456326	20030606
US 6855728	B2	20050215		

PRIORITY APPLN. INFO.: US 2001-896832 A2 20010629
OTHER SOURCE(S): MARPAT 138:198678

AB The invention is directed to small organic mols. having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer. Pharmaceutical compns. containing the modulators are also claimed.

IT **264616-91-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small-mol. modulators of hepatocyte growth factor/scatter factor activities as drugs)

RN 264616-91-3 HCAPLUS
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:915238 HCAPLUS
DOCUMENT NUMBER: 136:200148
TITLE: Screening mixtures: an experiment in pesticide lead generation
AUTHOR(S): Fisher, Karl J.; Felix, Ray A.; Oliver, Robert M.
CORPORATE SOURCE: Zeneca Agrochemicals, Richmond, CA, 94804, USA

SOURCE: ACS Symposium Series (2002), 800(Synthesis and Chemistry of Agrochemicals VI), 9-15
CODEN: ACSMC8; ISSN: 0097-6156
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Combinatorial libraries of potential herbicidal compds. were prepared by treatment of mixts. of 10 alkyl halides with heterocyclic nucleophiles; the products were then assayed for herbicidal activity. The screening of mixts. was evaluated as a way of improving the rate of new lead generation, one of the greatest challenges facing modern agricultural chemists. Herbicidal activity found in assays of the library compds. was linked in all cases either to a single compound from the mixture or to cumulative effects of multiple active compds. in a mixture The active compds. were prepared by individual synthesis upon deconvolution. The libraries led to various herbicidal compds., among which was triazolylthiobutyramide I, an active herbicide with a novel mode of action.

IT **401519-80-0P 401519-81-1P 401519-82-2P**
401519-83-3P
RL: AGR (Agricultural use); CPN (Combinatorial preparation); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of herbicidal compds. by nucleophilic substitution of alkyl halides with heterocyclic nucleophiles and active herbicidal compds. found in the libraries)

RN 401519-80-0 HCAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 401519-81-1 HCAPLUS
CN 1H-Pyrazole-1-hexanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 401519-82-2 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-α-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 401519-83-3 HCAPLUS
CN 1H-Pyrazole-1-pentanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:631412 HCAPLUS
DOCUMENT NUMBER: 131:243266
TITLE: Preparation of pyrazolyloximinoacetates and related compounds as agrochemical and industrial fungicides.
INVENTOR(S): Hirohara, Yoji; Sugano, Shigeyoshi; Nakashima, Hideki; Kimura, Takuo; Sakakibara, Takashi
PATENT ASSIGNEE(S): SDS Biotech K.K., Japan
SOURCE: Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 945437	A1	19990929	EP 1998-105673	19980327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			EP 1998-105673	19980327
OTHER SOURCE(S):	MARPAT 131:243266			

GI



I

AB Title compds. [I; X = CO2R1, CONHR1, CON(R1)2, cyano, 5-6 membered heteroaryl; Y = CH, N; W = alkylene, NR1, O; n = 0, 1; R = alkyl, haloalkyl; A, B, D = H, halo, R1, R1O, R1S, R1SO, R1SO2, (R1)2N, R1O2C, R1OR2, R1ON:CH, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (substituted) Ph, PhCH2, PhO, PhCH2O, PhOR2, PhS, PhCH2S, PhSR2, PhCH2ON:CH, naphthyl, heteroaryl; R1 = alkyl, haloalkyl; R2 = alkylene; provided that A, B, D do not all = H and >2 of A, B, D do not = aryl or heteroaryl], were prepared Thus, Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-hydroxyiminoacetate (preparation given) was stirred with Me2SO4 and K2CO3 in DMF to give 82% Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-methoxyiminoacetate. The latter at 500 ppm gave 100% prevention of Pseudoperonospora cubensis on cucumbers.

IT **244270-51-7P 244270-52-8P 244270-53-9P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyloximinoacetates and related compds. as agrochem. and industrial fungicides)

RN 244270-51-7 HCAPLUS

CN 1H-Pyrazole-1-acetic acid, α-(methoxymethylene)-3-methyl-4-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 244270-52-8 HCAPLUS

CN 1H-Pyrazole-1-acetamide, α-(methoxymethylene)-N,3-dimethyl-4-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 244270-53-9 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, α-(methoxymethylene)-3-methyl-4-(3-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:572284 HCAPLUS
DOCUMENT NUMBER: 129:212968
TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as insecticides
INVENTOR(S): Jacobson, Richard Martin
PATENT ASSIGNEE(S): Rohm and Haas Co., USA
SOURCE: U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 415,117, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5798311	A	19980825	US 1995-468284	19950606
ZA 9105394	A	19920325	ZA 1991-5394	19910711
PRIORITY APPLN. INFO.:			US 1990-553220	B2 19900713
			US 1991-713692	B3 19910617
			US 1993-49891	B1 19930419
			US 1995-415117	B2 19950329

OTHER SOURCE(S): MARPAT 129:212968
GI



I

AB The N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides I [R, R1 = H, halo, (halo)alkyl, (halo)alkoxy, nitro, etc.; R2 = H, halo, haloalkyl or haloalkoxy; R3 = halo, haloalkyl or haloalkoxy; V = H, alkyl, alkylcarbonyl, alkoxycarbonyl or formyl; Y1 = H, alkyl, alkenyl, alkynyl, (halo)phenyl, etc.; Y2 = H, alkyl, alkoxycarbonyl, cyano, etc.] and I salts are prepared as insecticides.

IT **141128-27-0P 141128-28-1P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as insecticide)

RN 141128-27-0 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 141128-28-1 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:411990 HCAPLUS
DOCUMENT NUMBER: 127:81368
TITLE: Synthesis of some new oximes, thiocarbamates, pyrazolyloxy, isoxazolyloxy, pyrimidyloxy and pyridyloxy quinolines
AUTHOR(S): Abdel Hafez, Ali A.
CORPORATE SOURCE: Chem. Dep., Fac. Sci., Assiut Univ., Assiut, Egypt
SOURCE: Qatar University Science Journal (1994), 14(Spec. Issue), 108-113
CODEN: QUSJEV; ISSN: 1023-8948
PUBLISHER: University of Qatar, Faculty of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The reaction of I or its corresponding chalcones with hydroxylamine in boiling pyridine gave oximes in almost quant. yield. Reaction of the oximes with Ph isothiocyanate gave the corresponding thiocarbamates. A new series of pyrazolyloxy-, isoxazolyloxy-, pyrimidyloxy-, and pyridyloxy-substitute quinolines were obtained. The in vitro antibacterial and antifungal activity were screened for all the compds. prepared; some of the compds. tested showed interesting results.

IT **191873-96-8P 191873-97-9P 191873-98-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, bactericidal, and fungicidal activity of (morpholinosulfonyl)quinolines)

RN 191873-96-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-phenyl- (9CI) (CA INDEX NAME)



RN 191873-97-9 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 191873-98-0 HCAPLUS

CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:262919 HCAPLUS
DOCUMENT NUMBER: 127:5038
TITLE: Synthesis, reaction, theoretical calculation, NMR study and x-ray crystal structure of 1-substituted and 1-unsubstituted 1H-pyrazol-5(2H)-ones
AUTHOR(S): Attanasi, Orazio A.; De Crescentini, Lucia; Filippone, Paolino; Foresti, Elisabetta; Galeazzi, Roberta; Ghiviriga, Ion; Katritzky, Alan R.
CORPORATE SOURCE: Facolta Scienze, Univ. Urbino, Urbino, 61029, Italy
SOURCE: Tetrahedron (1997), 53(15), 5617-5640
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1-Substituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones have been prepared by the reaction of conjugated azoalkenes with alcs., thiols, and phenols. In some cases the intermediate hydrazones were isolated, while in others the products were obtained in one step. 1-Unsubstituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones were produced by methanolysis of the corresponding 1-substituted derivs. under reflux. Some of these compds. were studied by mol. mechanics calcns., as well as deuterium induced shifts (DIS) on 13C chemical shifts, and tentative conclusion was drawn about their tautomerism and conformations. X-Ray crystal structure detns. of 1-(aminocarbonyl)-3-methyl-4-methoxy-1H-pyrazol-5(2H)-one and 3-methyl-4-methoxy-1H-pyrazol-5(2H)-one demonstrated that both mols. exist in the crystal exclusively in the HN-CO tautomeric form. Some previously reported structural assignments in some pyrazolones and hydroxypyrazoles were corrected

IT **190257-08-0P 190257-09-1P 190257-14-8P**
190257-15-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, reaction, theor. calcn., NMR study and x-ray crystal structure of 1H-pyrazol-5(2H)-ones)

RN 190257-08-0 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo- (9CI) (CA INDEX NAME)



RN 190257-09-1 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 190257-14-8 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy- (9CI) (CA INDEX NAME)



RN 190257-15-9 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:35296 HCAPLUS
DOCUMENT NUMBER: 124:90281
TITLE: Preparation of 1H-imidazo[1,2-b]pyrazole derivatives
INVENTOR(S): Sato, Tadahisa; Matsuoka, Mitsuyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07278455	A2	19951024	JP 1994-68738	19940406

PRIORITY APPLN. INFO.: JP 1994-68738 19940406
OTHER SOURCE(S): MARPAT 124:90281
GI



I

AB The title compds. I (R1-2 = H, substituent; R3 = H, halo, alkoxy, etc.; R4

= alkyl, aryl; n = 0-2), useful as starting materials for color photog. couplers and dyes, are prepared from 5-amino-1H-pyrazole derivs. Acylating 5-amino-4-chloro-3-methyl-1H-pyrazole with BrCH2COPh in the presence of γ-collidine, reacting the product with PhSSPh in the presence of NaH, and heating at 60° in the presence of HCl gave I (R1 = Me; R2, R4 = Ph; R3 = Cl; n = 0).

IT **172887-69-3P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 172887-69-3 HCAPLUS

CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl-2-(phenylthio)- (9CI) (CA INDEX NAME)



IT **172887-64-8P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with di-Ph disulfide)

RN 172887-64-8 HCAPLUS

CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:677721 HCAPLUS
DOCUMENT NUMBER: 123:183352
TITLE: Silver halide color photographic materials containing timing DIR-couplers
INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07084348	A2	19950331	JP 1993-229118	19930914
PRIORITY APPLN. INFO.:			JP 1993-229118	19930914
OTHER SOURCE(S):	MARPAT 123:183352			

GI



I

AB The photog. materials with Ag halide emulsions on supports contain I (R, R1 = H, substituent or ring atom; DI = development inhibitor; TIME = timing group which retards the DI-releasing process; n = 0-2); the development inhibitor is released by reaction with the oxidized developing agent. Image sharpness and storage stability are improved.

IT **167381-31-9 167381-35-3 167381-36-4**
RL: TEM (Technical or engineered material use); USES (Uses)

(pyrazolidone photog. development inhibitor-releasing coupler)

RN 167381-31-9 HCAPLUS

CN 1-Pyrazolidineacetic acid, 4-[4-[[[5-amino-4-(2-propenyl)-4H-1,2,4-triazol-3-yl]thio]methyl]-2-[(methylsulfonyl)amino]phenoxy]-3,5-dioxo-2-(2,4,6-trichlorophenyl)-, 1-[(decyloxy)carbonyl]pentyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Me

RN 167381-35-3 HCAPLUS

CN 1-Pyrazolidinecarboxylic acid, 4-[4-[(3-carboxy-1-oxopropyl)amino]-2-[[(4,5,6,7-tetrahydro-2-benzothiazolyl)thio]methyl]phenoxy]-3,5-dioxo-2-phenyl-, 1-[2-oxo-2-(tetradecyloxy)ethyl] ester (9CI) (CA INDEX NAME)



RN 167381-36-4 HCAPLUS
CN 3,5-Pyrazolidinedione, 1-acetyl-4-[2-nitro-4-[1-[(1-phenyl-1H-tetrazol-5-yl)thio]undecyl]phenoxy]-2-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:547587 HCAPLUS
DOCUMENT NUMBER: 123:44276
TITLE: Photographic magenta coupler having dioxopyrazolidine nucleus
INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07036159	A2	19950207	JP 1993-179283	19930720
JP 3208694	B2	20010917		
PRIORITY APPLN. INFO.:			JP 1993-179283	19930720

OTHER SOURCE(S): MARPAT 123:44276
GI



I

AB The coupler has a structure I (R1, R2 = H, substituent; R1 and R2 may form a ring; X = H, leaving group released by the coupling reaction with the developer oxidant). The magenta coupler giving a dye with an excellent stability to light, heat, and humidity.

IT **163970-11-4 163970-15-8 163970-18-1 163970-19-2**
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. magenta coupler having dioxopyrazolidine nucleus)

RN 163970-11-4 HCAPLUS

CN 1-Pyrazolidineacetic acid, α-(1,1-dimethylethyl)-4-(2-methylphenoxy)-3,5-dioxo-2-phenyl-, decyl ester (9CI) (CA INDEX NAME)



RN 163970-15-8 HCAPLUS

CN 3,5-Pyrazolidinedione, 4-(4-nitrophenoxy)-1-(1-oxotridecyl)-2-phenyl-(9CI) (CA INDEX NAME)



RN 163970-18-1 HCAPLUS
CN 3,5-Pyrazolidinedione, 1-(1-ethyloctyl)-2-(2-methoxyethyl)-4-(2-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 163970-19-2 HCAPLUS
CN 1-Pyrazolidineacetic acid, 2-[2-(hexadecylamino)-2-oxoethyl]-4-[4-[(1-methylethoxy)carbonyl]phenoxy]-3,5-dioxo-, methyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:214493 HCAPLUS
DOCUMENT NUMBER: 116:214493
TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as pesticides
INVENTOR(S): Jacobson, Richard Martin
PATENT ASSIGNEE(S): Rohm and Haas Co., USA
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 466408	A1	19920115	EP 1991-306113	19910704
EP 466408	B1	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 188690	E	20000115	AT 1991-306113	19910704
ES 2143459	T3	20000516	ES 1991-306113	19910704
CA 2046420	AA	19920114	CA 1991-2046420	19910705
AU 9180313	A1	19920116	AU 1991-80313	19910710
AU 652762	B2	19940908		
ZA 9105394	A	19920325	ZA 1991-5394	19910711
BR 9102980	A	19920211	BR 1991-2980	19910712
HU 58702	A2	19920330	HU 1991-2355	19910712
JP 06080642	A2	19940322	JP 1991-172304	19910712
JP 3321186	B2	20020903		
AU 9480323	A1	19950413	AU 1994-80323	19941208
AU 680315	B2	19970724		

PRIORITY APPLN. INFO.: US 1990-553220 A 19900713
US 1991-713692 A 19910617

OTHER SOURCE(S): MARPAT 116:214493
GI



I



II

AB Title compds. [I; A = (hetero)aryl; Y = isothiocyanato, isocyano, amino, alkanoyloxy, alkoxy, PhO, alkylthio, phenylthio; Z = H, alkyl; B = (hetero)aryl; U = O, S; V = H, alkyl, alkoxyalkyl, alkylthioalkyl, CHO, alkylcarbonyl, CO2H, PhO, alkoxycarbonyloxy, alkylsulfonyl, PhS, etc.], were prepared Thus, N-(4-trifluoromethylphenyl)-3-(4-chlorophenyl)-4-carbomethoxy-4-methyl-4,5-dihydro-1H-pyrazole-1-carboxamide was converted successively to the 4-acid, 4-carbonyl chloride, 4-azidocarbonyl derivative, 4-isocyanato derivative and finally to title carboxamide II. II as 600 ppm sprays gave complete control of Epilachna varivestis, Spodoptera eridonia, and Anthonomus gradis grandis.

IT **141128-27-0P 141128-28-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pesticide)

RN 141128-27-0 HCAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-[4-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 141128-28-1 HCAPLUS
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1977:535318 HCAPLUS
DOCUMENT NUMBER: 87:135318
TITLE: 3,4-Disubstituted 2-(β-naphthyloxy)ethylpyrazolones
INVENTOR(S): Moeller, Eike; Meng, Karl; Seuter, Friedel; Horstmann, Harald
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 49 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2554701	A1	19770608	DE 1975-2554701	19751205
SE 7613536	A	19770606	SE 1976-13536	19761202
NL 7613451	A	19770607	NL 1976-13451	19761202
BE 849047	A1	19770603	BE 1976-172954	19761203
DK 7605456	A	19770606	DK 1976-5456	19761203
JP 52071467	A2	19770614	JP 1976-144842	19761203
FR 2333505	A1	19770701	FR 1976-36543	19761203
ES 453908	A1	19771116	ES 1976-453908	19761203

PRIORITY APPLN. INFO.: DE 1975-2554701 A 19751205

GI



I

AB Title compds. I (R = Me, R1 = Et, Bu, hexyl, CH2CH2OEt, Ph, CH2CH2OPh, SCF3, OPh, R = Et, R1 = Me, R2 = H, Br) were prepared by condensing 2-(2-naphthyloxy)ethylhydrazines with RCOCHR1CO2Et. I (R = Me, R1 = hexyl, R2 = H) at 10 mg caused 51% inhibition of thrombus formation in rats.

IT **64076-70-6P 64076-73-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 64076-70-6 HCAPLUS

CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[2-(2-naphthalenyloxy)ethyl]-4-phenoxy- (9CI) (CA INDEX NAME)



RN 64076-73-9 HCAPLUS

CN 3H-Pyrazol-3-one, 2-[2-[(5-bromo-2-naphthalenyl)oxy]ethyl]-2,4-dihydro-5-methyl-4-phenoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1974:403821 HCAPLUS
DOCUMENT NUMBER:	81:3821
TITLE:	Phosgene immonium salts. XIII. Dichloromalonyl cyanines and 3,5-bis(dimethylamino)pyrazoles
AUTHOR(S):	De Voghel, Guy J.; Eggerichs, Terry L.; Janousek, Zdenek; Viehe, Heinz G.
CORPORATE SOURCE:	Lab. Chim. Org., Univ. Louvain, Louvain-la-Neuve, Belg.
SOURCE:	Journal of Organic Chemistry (1974), 39(9), 1233-5 CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE:	Journal

LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The chloromalonyl cyanine derivs. (I,R = alkyl, aryl, halo, alkoxy) were synthesized by the reaction of RCH2CONMe2 with Cl2C:N+Me2 Cl-. The biselectrophilic system in I is of general applicability to the synthesis of aminated heterocyclic systems. I reacts with hydrazines NH2NHR1 (R1 = Me, Ph, PhSO2 etc.) to give 3,5-bis(dimethylamino)pyrazoles, II.
IT **50860-18-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50860-18-9 HCAPLUS
CN 1H-Pyrazole-1-carboxylic acid, 3,5-bis(dimethylamino)-4-phenoxy-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1972:488382 HCAPLUS
DOCUMENT NUMBER: 77:88382
TITLE: 1-Phenyl-2-acyl-3-amino-2-pyrazolin-5-ones from 1-phenyl 3-azidocarbonyl-2-pyrazolin-5-ones
AUTHOR(S): Hendess, Raymond W.
CORPORATE SOURCE: Res. Lab., Eastman Kodak Co., Rochester, NY, USA
SOURCE: Journal of Organic Chemistry (1972), 37(15), 2400-1
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 77:88382
AB The Curtius reaction of 1-phenyl-3-azidocarbonyl-2-pyrazolin-5-one in HOAc leads to 1-phenyl-2-acetyl-3-amino-3-pyrazolin-5-one rather than the expected 1-phenyl-3-acetamido-2-pyrazolin-5-one.
IT **34804-14-3P 34804-15-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34804-14-3 HCAPLUS
CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 34804-15-4 HCAPLUS

CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-(4-methylphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



```
=> d que l14
L1                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L3           203 SEA FILE=REGISTRY SSS FUL L1
L9                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L11            2 SEA FILE=REGISTRY SSS FUL L9
L12            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11(L)(RACT OR RCT OR RGT)/RL

L13           15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L)PREP/RL
L14            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 AND L13
```

=> d l14 ibib abs hitstr 1-2

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:253142 HCAPLUS
DOCUMENT NUMBER: 140:287377
TITLE: Preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in the treatment of AIDS
INVENTOR(S): Mowbary, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024147	A1	20040325	WO 2003-IB3946	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132793	A1	20040708	US 2003-661947	20030912

PRIORITY APPLN. INFO.:

GB 2002-21477	A	20020916
GB 2002-23354	A	20021008
US 2002-433397P	P	20021213

GI



I

AB This invention relates to 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile (shown as I) and pharmaceutically acceptable salt, solvate or derivs. thereof, to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates used in such processes. I binds to the enzyme reverse transcriptase (IC50 = 295 nM) and is an inhibitor thereof. I had t1/2 >120 min in human liver microsomes and Supermix; it had an unbound hepatocyte clearance <9 mL/min/kg in human hepatocytes. Reverse transcriptase is implicated in the infectious life cycle of Human Immunodeficiency Virus (HIV). Compds. which interfere with the function of this enzyme showed utility in the

treatment of conditions caused by HIV and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS) (no data). Two examples of the preparation of I are given: cyclocondensation of 2-hydroxyethylhydrazine with 5-[1-(cyclopropylcarbonyl)-2-oxopropoxy]isophthalonitrile (and separation of regioisomers) and deprotection of 5-[[3-cyclopropyl-5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile; preparation of the reactants is described.

IT **675198-29-5P**, 5-[[3-Cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(drug candidate; preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)

RN 675198-29-5 HCAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **675198-31-9P**, 5-[1-(Cyclopropylcarbonyl)-2-oxopropoxy]isophthalonitrile **675198-33-1P**, 5-[[3-Cyclopropyl-5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)

RN 675198-31-9 HCAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[1-(cyclopropylcarbonyl)-2-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 675198-33-1 HCAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-5-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **675198-30-8P**, 5-[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **675198-34-2P**, 5-[[5-Cyclopropyl-3-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)
RN 675198-30-8 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 675198-34-2 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:832763 HCAPLUS
DOCUMENT NUMBER: 137:337884
TITLE: Preparation of aryloxy pyrazole derivatives as reverse transcriptase inhibitors for treating HIV
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, Davis Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085860	A1	20021031	WO 2002-IB1234	20020404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

EE 200300497	A	20040216	EE 2003-497		20020404
BR 2002008811	A	20040309	BR 2002-8811		20020404
JP 2004531535	T2	20041014	JP 2002-583387		20020404
US 2003100554	A1	20030529	US 2002-118512		20020405
ZA 2003007095	A	20040910	ZA 2003-7095		20030910
NO 2003004523	A	20031209	NO 2003-4523		20031009
PRIORITY APPLN. INFO.:			GB 2001-8999	A	20010410
			GB 2001-27426	A	20011115
			US 2001-289570P	P	20010508
			US 2002-346727P	P	20020107
			WO 2002-IB1234	W	20020404

OTHER SOURCE(S): MARPAT 137:337884

GI



I

AB This invention relates to pyrazole derivs. (shown as I; e.g. 2-Amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined below, and to processes for the preparation thereof, intermediates used in their preparation of, compns. containing them and the uses of such derivs. The compds. of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compds. of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). In tests of inhibition of HIV-1 reverse transcriptase enzyme, the claimed compds. 2-amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone, 3,5-dimethyl-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile and 1-(3-azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole had IC50 values of 39,000, 3,200 and 248 nM, resp. In I: R1 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R10, -CONR5R10, R8 or R9. R2 is H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ph, benzyl, R8 or R9; or, R1 and R2, when taken together, represent unbranched C3-C4 alkylene. R3 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R5, -CONR5R5, R8 or R9; R4 is Ph, naphthyl or pyridyl. Definitions of R5 and R7-R10 and addnl. specifications are given in the claims. Included are 283 claimed-compound prepns. and 115 intermediate prepns.

IT **473919-45-8P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol **473919-54-9P**, Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate **473919-56-1P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetohydrazide **473919-83-4P**, 2-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473920-32-0P**, Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate **473920-89-7P**, 5-[[1-(2-Hydroxyethyl)-3-

isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-04-9P**, 3-Chloro-5-[[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy]benzonitrile **473921-10-7P**, 3-Fluoro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-11-8P**, 3-Methyl-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-12-9P**, 3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-50-5P**, 5-[[3-tert-Butyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-56-1P**, 3-(1H-Pyrazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-60-7P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide **473921-63-0P**, 5-[[5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-73-2P**, 5-[[3,5-Diethyl-1-((methoxycarbonyl)methyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile **473921-85-6P**, 3-[[3-Cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile **473921-96-9P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile **473922-65-5P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfanyl)benzonitrile **473922-87-1P**, 5-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile **473923-08-9P**, Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl phosphate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)

RN 473919-45-8 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473919-54-9 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 473919-56-1 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, hydrazide (9CI) (CA INDEX NAME)



RN 473919-83-4 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473920-32-0 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3-cyanophenoxy)-3,5-diethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 473920-89-7 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-(2-hydroxyethyl)-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-04-9 HCAPLUS
CN Benzonitrile, 3-chloro-5-[[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-10-7 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473921-11-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-12-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-50-5 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-56-1 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-60-7 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473921-63-0 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-1-(2-hydroxyethyl)-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-73-2 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dicyanophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 473921-85-6 HCAPLUS
CN Benzonitrile, 3-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-96-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 473922-65-5 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 473922-87-1 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-08-9 HCAPLUS
CN Phosphoric acid, 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT **473919-46-9P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-55-0P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide **473919-62-9P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473919-65-2P**, 2-[4-(2,6-Dimethyl-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-66-3P**, 2-[4-(2-Chloro-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-67-4P**, 2-[4-(4-Fluoro-3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-68-5P**, 2-[4-(4-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-69-6P**, 2-[4-(3-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-70-9P**, 2-[4-(2-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-71-0P**, 2-[4-(2,6-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-72-1P**, 2-[4-(2,3-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-73-2P**, 2-[4-(2,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-74-3P**, 2-[3,5-Diethyl-4-(2-fluorophenoxy)-1H-pyrazol-1-yl]ethanol **473919-75-4P**, 2-[3,5-Diethyl-4-(3-

fluorophenoxy)-1H-pyrazol-1-yl]ethanol **473919-76-5P**, 2-[4-(3,5-Dimethylphenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-77-6P**, 2-[4-(3-Methyl-4-fluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-78-7P**, 2-[4-(2,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-79-8P**, 2-[4-(2,3-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-80-1P**, 2-[4-(3,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-81-2P**, 2-[4-(2,6-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-82-3P**, 2-[4-(2,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-84-5P**, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazole **473919-86-7P**, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)-1H-pyrazole **473920-14-8P**, 1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-2-propanol **473920-16-0P**, 2-[2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethoxy]ethanamine **473920-21-7P**, 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1H-pyrazol-1-yl]ethanol **473920-29-5P**, 2-[4-(3-Cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide **473920-87-5P**, 2-[4-(3,5-Dichlorophenoxy)-3-methyl-5-[[[(3-pyridinyl)methyl]amino]methyl]-1H-pyrazol-1-yl]ethanol **473921-05-0P**, 3-Chloro-5-[[5-[[(4-cyanobenzyl)amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]benzonitrile **473921-13-0P**, 3-Chloro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-39-0P**, 3-[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-48-1P**, 3-[[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473921-52-7P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,4-triazol-1-yl)benzonitrile **473921-53-8P**, 3-(1,4-Dihydro-4-oxo-1-pyridyl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-54-9P**, 3-(1H-1,2,3-Triazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-55-0P**, 3-(2H-1,2,3-Triazol-2-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-57-2P**, 3-(1,2-Dihydro-2-oxo-1-pyridyl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-58-3P**, 3-(2,3-Dihydro-3-oxo-1,2-diazin-2-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-59-4P**, 3-(2,5-Dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-61-8P**, 5-[[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-62-9P**, 5-[[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-64-1P**, 5-[[3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-65-2P**, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate **473921-69-6P**, 5-[[3,5-Diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-71-0P**, 5-[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile **473921-74-3P**, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide **473921-75-4P**, 5-[[3,5-Diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-83-4P**, 5-[[3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-86-7P**, 3-[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile **473921-91-4P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxybenzonitrile **473921-92-5P** **473921-93-6P** **473921-94-7P**, 2-[4-[3,5-Bis(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473921-95-8P**, 2-[3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1H-pyrazol-1-yl]ethanol **473922-01-9P**

, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-[(2-pyridinyl)methyl]acetamide **473922-67-7P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)benzonitrile **473922-70-2P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)benzonitrile **473922-73-5P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile **473922-74-6P**, 3-(2-(Methylamino)ethoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-77-9P**, 3-((Aminocarbonyl)methoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-79-1P**, 3-(2-Methoxyethoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-85-9P**, 3-Fluoro-5-[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-89-3P**, 3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzamide **473922-93-9P**, 5-[[5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473922-94-0P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile **473922-96-2P**, 3-(5-Methyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-98-4P**, 3-(5-Ethyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473922-99-5P**, 3-(5-Isopropyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473923-11-4P**, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl dihydrogen phosphate **473923-14-7P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monosulfate **473923-17-0P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile mono(benzenesulfonate) **473923-20-5P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monotosylate **473923-24-9P**, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monomesylate **473924-71-9P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)benzamide **473924-72-0P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)benzamide **473924-73-1P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)benzamide **473924-74-2P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,3-dimethyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;
USES (Uses)
(drug candidate; preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)

RN 473919-46-9 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-55-0 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-62-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473919-65-2 HCAPLUS
CN Benzonitrile, 4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-3,5-

dimethyl- (9CI) (CA INDEX NAME)



RN 473919-66-3 HCAPLUS
CN Benzonitrile, 3-chloro-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473919-67-4 HCAPLUS
CN Benzonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 473919-68-5 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(4-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-69-6 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-70-9 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-71-0 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,6-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-72-1 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,3-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-73-2 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-74-3 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 473919-75-4 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(3-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 473919-76-5 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dimethylphenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-77-6 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(4-fluoro-3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 473919-78-7 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA

INDEX NAME)



RN 473919-79-8 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,3-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-80-1 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-81-2 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,6-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-82-3 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-84-5 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 473919-86-7 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 473920-14-8 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl-α-methyl- (9CI) (CA INDEX NAME)



RN 473920-16-0 HCAPLUS
CN Ethanamine, 2-[2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 473920-21-7 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-ethyl-5-methoxy- (9CI) (CA INDEX NAME)



RN 473920-29-5 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3-cyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473920-87-5 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-methyl-5-[[(3-

pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 473921-05-0 HCAPLUS
CN Benzonitrile, 3-chloro-5-[[5-[[[(4-cyanophenyl)methyl]amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-13-0 HCAPLUS
CN Benzonitrile, 3-chloro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-39-0 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-48-1 HCAPLUS
CN Benzonitrile, 3-[[5-(aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473921-52-7 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-53-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(4-oxo-1(4H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473921-54-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-55-0 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2H-1,2,3-triazol-2-yl)- (9CI) (CA INDEX NAME)



RN 473921-57-2 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473921-58-3 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 473921-59-4 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-61-8 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-62-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-64-1 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-65-2 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[(aminocarbonyl)oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-69-6 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-71-0 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-

yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-74-3 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dicyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473921-75-4 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-83-4 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-86-7 HCAPLUS
CN Benzonitrile, 3-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-91-4 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 473921-92-5 HCAPLUS

CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 473921-93-6 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 473921-94-7 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-di-1H-pyrazol-1-ylphenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473921-95-8 HCAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 473922-01-9 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 473922-67-7 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 473922-70-2 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 473922-73-5 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473922-74-6 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473922-77-9 HCAPLUS
CN Acetamide, 2-[3-cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-

yl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 473922-79-1 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 473922-85-9 HCAPLUS
CN Benzonitrile, 3-fluoro-5-[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-89-3 HCAPLUS
CN Benzamide, 3-cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-93-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-94-0 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473922-96-2 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-

methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473922-98-4 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473922-99-5 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473923-11-4 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[2-(phosphonooxy)ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-14-7 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 473923-17-0 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monobenzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 473923-20-5 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 473923-24-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 473924-71-9 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-72-0 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473924-73-1 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 473924-74-2 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



IT **473923-41-0P**, Ethyl 4-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-3-oxobutanoate **473923-43-2P**, [4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetic acid **473923-49-8P**, 1-Acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole **473923-52-3P**, 1-Acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole **473923-61-4P**, 4-(3,5-Dichlorophenoxy)-5-ethyl-2-(2-hydroxyethyl)-2,4-dihydro-3H-pyrazol-3-one **473923-63-6P**, 2-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-3H-pyrazol-3-one **473923-65-8P**, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl trifluoromethanesulfonate **473923-70-5P**, 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile **473923-73-8P**, 3-[[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473923-77-2P**, N-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl]-N-[(3-pyridinyl)methyl]amine **473923-85-2P**, 5-[[1-[2-[[tert-Butyldimethylsilyl]oxy]ethyl]-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473923-89-6P**, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole **473923-91-0P**, 5-(Bromomethyl)-1-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazole **473923-92-1P**, 3-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473923-93-2P**, 3-[[5-(Bromomethyl)-1-[2-[[tert-butyldimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473923-94-3P**, 3-[[5-(Aminomethyl)-1-[2-[[tert-butyldimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473924-05-9P**, 1-Cyclopropyl-2-(3,5-dicyanophenoxy)-1,3-pentanedione **473924-12-8P**, 3-[[1-[2-[[tert-Butyldimethylsilyl]oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile **473924-13-9P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile **473924-14-0P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide **473924-15-1P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)benzonitrile **473924-17-3P**, 5-[[3,5-Diethyl-1-[3-(tetrahydro-2H-pyran-2-yloxy)propyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile **473924-18-4P**, 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile **473924-19-5P**, 3-[[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile **473924-20-8P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,2-dihydro-2-oxo-1-pyridyl)benzonitrile **473924-21-9P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,6-dihydro-

6-oxo-1,2-diazin-1-yl)benzonitrile **473924-22-0P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)benzonitrile **473924-23-1P**, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile **473924-24-2P**, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile **473924-25-3P**, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile **473924-26-4P**, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile **473924-27-5P**, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile **473924-28-6P**, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile **473924-34-4P**, 4-(3,5-Difluorophenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole **473924-36-6P**, 4-[3,5-Bis(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole **473924-37-7P**, 3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole **473924-38-8P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile **473924-42-4P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(methylsulfanyl)benzonitrile **473924-43-5P**, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile **473924-44-6P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-(methylamino)ethoxy)benzonitrile **473924-45-7P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-((aminocarbonyl)methoxy)benzonitrile **473924-46-8P**, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)benzonitrile **473924-48-0P**, 3-Fluoro-5-[[5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473924-49-1P**, 3-Cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]benzamide **473924-50-4P**, 5-[(1-Acetyl-3,5-diethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile **473924-51-5P**, 5-[[1-Acetyl-3-(1-bromoethyl)-5-ethyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **473924-52-6P**, 5-[[5-Ethyl-3-(1-hydroxyethyl)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile **473924-53-7P**, 3-Cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-N'-hydroxybenzenecarboximidamide **473924-54-8P**, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzonitrile **473924-55-9P**, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-methyl-1,2,4-oxadiazol-3-yl]benzonitrile **473924-56-0P**, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-ethyl-1,2,4-oxadiazol-3-yl]benzonitrile **473924-57-1P**, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-isopropyl-1,2,4-oxadiazol-3-yl]benzonitrile
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)

RN 473923-41-0 HCAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 473923-43-2 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473923-49-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-52-3 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-

(9CI) (CA INDEX NAME)



RN 473923-61-4 HCAPLUS
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 473923-63-6 HCAPLUS
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 473923-65-8 HCAPLUS
CN Methanesulfonic acid, trifluoro-, 4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-

dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)



RN 473923-70-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-73-8 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-77-2 HCAPLUS
CN 3-Pyridinemethanamine, N-[[4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 473923-85-2 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-89-6 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-91-0 HCAPLUS
CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 473923-92-1 HCAPLUS
CN Benzonitrile, 3-chloro-5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-93-2 HCAPLUS
CN Benzonitrile, 3-[[5-(bromomethyl)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473923-94-3 HCAPLUS
CN Benzonitrile, 3-[[5-(aminomethyl)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473924-05-9 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[1-(cyclopropylcarbonyl)-2-oxobutoxy]- (9CI) (CA INDEX NAME)



RN 473924-12-8 HCAPLUS
CN Benzonitrile, 3-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473924-13-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473924-14-0 HCAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 473924-15-1 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-17-3 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-18-4 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyano-5-fluorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-19-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-fluorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-20-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 473924-21-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 473924-22-0 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-23-1 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-24-2 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyano-5-methylphenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-25-3 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-26-4 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dicyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-27-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-28-6 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-34-4 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-difluorophenoxy)-3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-36-6 HCAPLUS
CN 1H-Pyrazole, 4-(3,5-di-1H-pyrazol-1-ylphenoxy)-3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-37-7 HCAPLUS
CN 1H-Pyrazole, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-38-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 473924-42-4 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 473924-43-5 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473924-44-6 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473924-45-7 HCAPLUS
CN Acetamide, 2-[3-cyano-5-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 473924-46-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 473924-48-0 HCAPLUS
CN Benzonitrile, 3-fluoro-5-[[5-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-49-1 HCAPLUS
CN Benzamide, 3-cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-50-4 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473924-51-5 HCAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(1-bromoethyl)-4-(3,5-dicyanophenoxy)-5-ethyl- (9CI) (CA INDEX NAME)



RN 473924-52-6 HCAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-3-(1-hydroxyethyl)-1-[2-

[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-53-7 HCAPLUS
CN Benzenecarboximidamide, 3-cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 473924-54-8 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473924-55-9 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473924-56-0 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473924-57-1 HCAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'BEILSTEIN' ENTERED AT 15:16:11 ON 13 APR 2005

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON February 14, 2005

FILE COVERS 1771 TO 2004.
*** FILE CONTAINS 9,133,317 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW
* **PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.**
* **NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

=> d que l18
L5 STR



NODE ATTRIBUTES:
CONNECT IS E2 RC AT 13
CONNECT IS E1 RC AT 14

CONNECT IS E1 RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L18 0 SEA FILE=BEILSTEIN SSS FUL L5

FILE 'MARPAT' ENTERED AT 15:17:13 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 142 ISS 15)(20050408/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6841675 11 JAN 2005
DE 10351736 13 JAN 2005
EP 1498472 19 JAN 2005
JP 2005023199 27 JAN 2005
WO 2005021603 10 MAR 2005

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> d que l21
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L3 203 SEA FILE=REGISTRY SSS FUL L1
L5 STR



NODE ATTRIBUTES:
CONNECT IS E2 RC AT 13
CONNECT IS E1 RC AT 14
CONNECT IS E1 RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L6 2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L15 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
L19 1 SEA FILE=MARPAT SSS FUL L5
L21 0 SEA FILE=MARPAT ABB=ON PLU=ON L19 NOT L15

STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.